U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
π Gilead Sciences announced the FDA has granted priority review for a New Drug Application (NDA) of bictegravir plus lenacapavir (BIC/LEN).
π This investigational combination is designed as a once-daily single-tablet regimen for adults with HIV who are virologically suppressed.
ποΈ The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of August 27, 2026 for the review decision.
π¬ Chief Medical Officer Dietmar Berger stated the regimen combines bictegravir's high barrier to resistance with lenacapavir's novel capsid inhibitor mechanism.
π₯ The combination aims to provide sustained suppression for patients with comorbidities, prior ARV resistance, or those seeking to streamline complex regimens.
β Phase 3 trials ARTISTRY-1 and ARTISTRY-2 demonstrated comparable efficacy in maintaining virological suppression at Week 48.
β οΈ Both trials generally reported good tolerability with no significant or new safety concerns identified regarding the switch to BIC/LEN.
π ARTISTRY-1 included the oldest study population in a Phase 3 HIV treatment trial to date, focusing on aging patients with comorbidities.
π©Έ Week 48 data showed improvements in fasting lipid parameters and patient-reported treatment satisfaction when switching from complex regimens.
βοΈ ARTISTRY-2 confirmed that switching to BIC/LEN had no significant impact on weight compared to other treatments.
π Detailed results from ARTISTRY-1 were published in The Lancet on March 28, 2026, and presented at CROI 2026.
π§ͺ Bictegravir is a guideline-recommended integrase strand transfer inhibitor used only in combination with other antiretroviral agents.
π¬ Lenacapavir is a first-in-class capsid inhibitor approved globally for multi-drug-resistant HIV and as pre-exposure prophylaxis (PrEP).
β³ Lenacapavir inhibits HIV at multiple stages of its lifecycle and exhibits no known cross-resistance to other existing drug classes.
πΌ Gilead highlighted that BIC/LEN complements their existing portfolio, including the standard-of-care regimen Biktarvy which uses bictegravir with Descovy.
β οΈ The NDA submission is supported by positive data but the combination remains investigational and not approved globally for this specific use.
β Safety information notes a Boxed Warning for post-treatment acute exacerbation of Hepatitis B in patients discontinuing products containing emtricitabine or TDF.
π« Biktarvy should not be used with dofetilide or rifampin due to drug interaction risks and contraindications.
π₯ Lenacapavir is being further evaluated as a long-acting option in multiple ongoing clinical studies for HIV treatment and prevention.
- Gilead Sciences received FDA priority review for its new drug application of bictegravir plus lenacapavir, an investigational once-daily single-tablet combination regimen for HIV treatment.
- The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of August 27, 2026, providing a clear regulatory timeline for approval evaluation.
- BIC/LEN is supported by positive Phase 3 data from ARTISTRY-1 and ARTISTRY-2 trials demonstrating comparable efficacy in maintaining virological suppression at Week 48.
- The investigational treatment was generally well tolerated with no significant or new safety concerns identified across the clinical trials.
- ARTISTRY-1 enrolled the oldest study population in a Phase 3 HIV treatment registrational trial to date, expanding real-world applicability for aging patients.
- Week 48 data presented at CROI 2026 showed improvements in fasting lipid parameters and patient-reported treatment satisfaction when switching from complex regimens.
- ARTISTRY-2 confirmed that switching to BIC/LEN had no significant impact on weight, addressing a key patient concern regarding treatment side effects.
- Detailed results from ARTISTRY-1 were published in The Lancet on March 28, 2026, providing peer-reviewed validation of the program's progress.
- BIC/LEN combines bictegravir with lenacapavir, a first-in-class capsid inhibitor with no cross-resistance to other antiretrovirals, offering a novel mechanism of action.
- If approved, BIC/LEN has the potential to serve virologically suppressed patients including those who are aging, have comorbidities, or require streamlined treatment options.
- Lenacapavir is already approved in multiple countries for multi-drug-resistant HIV and as pre-exposure prophylaxis (PrEP), demonstrating its established safety and efficacy profile.
- The investigational regimen features a high barrier to resistance with bictegravir and lenacapavir, aligning with Gilead's portfolio cornerstone of Biktarvy.
- The investigational combination of bictegravir and lenacapavir (BIC/LEN) is not approved anywhere globally, meaning its safety and efficacy are not yet established for widespread use.
- While ARTISTRY trials showed comparable efficacy, there was no significant improvement in weight outcomes when switching from complex regimens.
- The PDUFA action date of August 27, 2026, is more than a year away, potentially delaying market entry and revenue recognition for this new product.
- Biktarvy, a core component of Gilead's portfolio, carries a boxed warning for post-treatment acute exacerbation of hepatitis B in patients with HIV-1 and HBV who discontinue the drug.
- Specific drug interactions prohibit the coadministration of Biktarvy with dofetilide or rifampin, limiting prescription flexibility for some patient populations.
- BIC/LEN is designated as an investigational treatment that has not been established as a complete HIV cure, despite claims about its high barrier to resistance.